Examples of using Progressionsfri in Danish and their translations into English
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Official/political
-
Computer
Progressionsfri overlevelse, Maj 2016 Nyhedsbrev, p.
Overlevelse(%; Kaplan- Meier- estimater) Progressionsfri.
Survival(%; Kaplan-Meier Estimates) Progression-Free.Progressionsfri overlevelse ifølge Binet stage ITT.
Progression-Free Survival according to Binet stage ITT.Det primære endpoint var progressionsfri overlevelse PFS.
The primary endpoint was progression-free survival PFS.Progressionsfri overlevelse i lokalt avanceret sygdom opdelt terapigruppe.
Progression-free survival in locally advanced disease by therapy sub-group.Undersøgelsens primære effektmål er progressionsfri overlevelse.
The primary efficacy endpoint of the study is progression-free survival.Progressionsfri overlevelse ved lokal avanceret sygdom, fordelt på behandlingsundergrupper.
Progression-free survival in locally advanced disease by therapy sub-group.De primære endepunkter var samlet overlevelse og progressionsfri overlevelse PFS.
The primary endpoints were overall survival and progression-free survival PFS.Tabel 1 Progressionsfri overlevelse ved lokalt avanceret sygdom pr. behandlingsundergruppe.
Table 1 Progression-free survival in locally advanced disease by therapy sub-group.Resultater vedrørende responsrate og progressionsfri overlevelse er givet i tabel 3.
Findings regarding response rate and progression-free survival are provided in Table 3.Varighed af MCyR, progressionsfri overlevelse og overordnet overlevelse var ensartet på tværs af de 4 behandlingsgrupper.
Durations of MCyR, progression-free survival, and overall survival were similar across the four treatment groups.Den primære effektparameter for forsøget var varigheden af progressionsfri overlevelse.
The primary efficacy parameter of the trial was the duration of progression-free survival.Den objektive responsrate og progressionsfri overlevelsestid blev signifikant forbedret med cetuximab.
Objective response rate and progression free survival time were significantly improved with cetuximab.Det primære endpoint for forsøget var objektiv responsrate og progressionsfri overlevelse.
The primary endpoints of the trial were objective response rate and progression-free survival.Det primære endepunkt, progressionsfri overlevelse(PFS), blev vurderet ved en uafhængig, blindet, central gennemgang.
The primary endpoint, progression-free survival(PFS), was assessed using a blinded independent central review.MabCampath viste sig at være chlorambucil overlegent målt ved det primære endepunkt progressionsfri overlevelse(PFS) se Figur 1.
MabCampath was shown to be superior to chlorambucil as measured by the primary endpoint progression free survival(PFS) see Figure 1.Progressionsfri overlevelse og objektiv responsrate var inferior i Avastin monoterapiarmen i forhold til FOLFOX- 4 armen.
Progression-free survival and objective response rate were inferior in the Avastin monotherapy arm compared to the FOLFOX-4 arm.Andre sekundære endpoint omfattede varighed af MCyR, progressionsfri overlevelse samt overordnet overlevelse.
Other secondary endpoints included duration of MCyR, progression-free survival, and overall survival.Progressionsfri overlevelse og total overlevelse for patienter med lokalt avanceret sygdom er vist i de følgende tabeller.
Progression-free survival and overall survival data for patients with locally advanced disease are summarised in the following tables.I begge undersøgelser var det primære grænsepunkt progressionsfri overlevelse(PFS) defineret ved MRI- scanning eller neurologisk forværring.
In both trials, the primary endpoint was progression-free survival(PFS) defined by MRI scans or neurological worsening.Hos de patienter med lokaliseret prostatacancer, som modtog Casodex alene,var der ingen signifikant forskel i progressionsfri overlevelse.
For patients with localised disease receiving CASODEX alone,there was no significant difference in progression free survival.Resultater for samlet responsrate, mediantid til sygdomsprogression og progressionsfri og samlet overlevelse, baseret på investigators vurderinger.
Results for overall response rate, median time to disease progression, and progression-free survival as assessed by the investigator.For patienter med lokaliseret sygdom, som fik bicalutamid som monoterapi,blev der ikke observeret signifikant forskel i progressionsfri overlevelse.
For patients with localised disease,receiving bicalutamide alone, there was no significant difference in progression free survival.Det primære endpoint for dette studie var progressionsfri overlevelse(PFS), baseret på studieinvestigatorernes vurdering af sygdomsprogression.
The primary endpoint of this trial was progression free survival(PFS), based on study investigators' assessment of disease Langtidssikkerheden for Kepivance er ikke fuldt ud evalueret med hensyn til generel overlevelse, progressionsfri overlevelse og sekundære maligniteter.
The long-term safety of Kepivance has not been fully evaluated with respect to overall survival, progression free survival and secondary malignancies.Th år uden behandling, progressionsfri i vagt-og-vent og forventer at bo som dette for mange, mange flere år på ingen lille del tak til dig!… Niko.
Th year without treatment, progression free in watch-and-wait and expect to stay like this for many, many more years in no small part thanks to you!… Niko.Forsøg BO17704 har vist, at bevacizumab givet som både 7, 5 mg/ kg legemsvægthver 3. uge og 15 mg/ kg legemsvægt hver 3. uge øger progressionsfri overlevelse og responsraten.
Study BO17704 has demonstrated that both 7.5 mg/ kg/ q3wk and15 mg/ kg/ q3wk bevacizumab doses increase progression free survival and response rate.Progressionsfri overlevelse hos patienter med RCC var signifikant længere i Nexavargruppen(163 dage) end i placebogruppen(41 dage) p 0, 0001, HR 0, 29.
Progression-free survival in patients with RCC was significantly longer in the Nexavar group(163 days) than in the placebo group(41 days) p 0.0001, HR 0.29.I en interimanalyse baseret på 947 randomiserede patienter blev der observeret forkortet progressionsfri overlevelsestid og forøget antal dødsfald hos patienter, der fik Vectibix sammen med bevacizumab og kemoterapi.
In an interim analysis based on 947 randomized patients, shortened progression free survival time and increased deaths were observed in the patients receiving Vectibix in combination with bevacizumab and chemotherapy.Med hensyn til progressionsfri overlevelse blev der set yderst statistisk signifikante resultater for højdosis paclitaxel- armen sammenlignet med etoposid/ cisplatin p=0. 007.
With respect to progression free survival, highly statistically significant results were noted for the high-dose paclitaxel arm compared to etoposide/ cisplatin p= 0.007.
